<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03745885</url>
  </required_header>
  <id_info>
    <org_study_id>YN011A</org_study_id>
    <nct_id>NCT03745885</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy and Safety of Supaglutide in Healthy Participants</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study the Efficacy and Safety of Supaglutide in Chinese Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of&#xD;
      the investigational drug Supaglutide proposed dosing once (or twice) weekly in Chinese&#xD;
      healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 4, 2018</start_date>
  <completion_date type="Actual">December 13, 2019</completion_date>
  <primary_completion_date type="Actual">June 10, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic：Cmax of Supaglutide</measure>
    <time_frame>baseline and up to 29 days after formal dose</time_frame>
    <description>Maximum Concentration(Cmax) of Supaglutide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: Tmax of Supaglutide</measure>
    <time_frame>baseline and up to 29 days after formal dose</time_frame>
    <description>Time to maximum plasma concentration (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: AUC0-t of Supaglutide</measure>
    <time_frame>baseline and up to 29 days after formal dose</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC0-t)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: t½ of Supaglutide</measure>
    <time_frame>baseline and up to 29 days after formal dose</time_frame>
    <description>Terminal elimination half-life in plasma (t½)</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>0.15mg Supaglutide or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.15 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.375mg Supaglutide or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.375 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.75mg Supaglutide or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.75 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.5mg Supaglutide or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.0mg Supaglutide or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.0 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Supaglutide injection</intervention_name>
    <description>Administered SC in the Supaglutide arms.</description>
    <arm_group_label>0.15mg Supaglutide or placebo</arm_group_label>
    <arm_group_label>0.375mg Supaglutide or placebo</arm_group_label>
    <arm_group_label>0.75mg Supaglutide or placebo</arm_group_label>
    <arm_group_label>1.5mg Supaglutide or placebo</arm_group_label>
    <arm_group_label>3.0mg Supaglutide or placebo</arm_group_label>
    <other_name>Diabegone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC in the placebo arms and to maintain the blind in the Supaglutide injection arms.</description>
    <arm_group_label>0.15mg Supaglutide or placebo</arm_group_label>
    <arm_group_label>0.375mg Supaglutide or placebo</arm_group_label>
    <arm_group_label>0.75mg Supaglutide or placebo</arm_group_label>
    <arm_group_label>1.5mg Supaglutide or placebo</arm_group_label>
    <arm_group_label>3.0mg Supaglutide or placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy subjects between 18 and 45 years old（inclusive）.&#xD;
&#xD;
          2. Body mass index（BMI）is between 18 and 28 kg/m2 (inclusive). The weight of male&#xD;
             subjects should not be less than 50 kg, and female subjects should not be less than 45&#xD;
             kg.&#xD;
&#xD;
          3. The female participant with reproductive potential, will be required a negative&#xD;
             pregnancy test before trial, maintaining non-pregnancy during the whole study period&#xD;
             and contraception 3 months after formal injection.&#xD;
&#xD;
          4. Participants must sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have a history of allergic reaction or hypersensitivity to the study drugs, or who&#xD;
             develop allergic reaction.&#xD;
&#xD;
          2. Have an evidence of Fasting blood-glucose greater than (&gt;) 6.0 mmol/L or less than (&lt;)&#xD;
             3.9 mmol/L, or hemoglobin A1c (HbA1c) greater than or equal to (&gt;=) 6.5 percent (%);&#xD;
&#xD;
          3. Have evidence of Sitting Blood ( take a break for five minutes) , systolic pressure&#xD;
             exceeds the range of 90 to 140 mmHg, or diastolic pressure exceeds the range of 50 to&#xD;
             90 mmHg, or Heart Rate exceeds the range of 50 bpm to100 bpm (including critical&#xD;
             value)&#xD;
&#xD;
          4. Have an evidence of ECG abnormalities including QTc &gt;450 msec or QRS complex &gt;120&#xD;
             msec. If QT Corrected &gt;450 msec; or QRS &gt;120msec, subject should Repeat the ECG&#xD;
             measurements twice and use the average of the QTc or QRS values measured to determine&#xD;
             whether the subjects are eligible.&#xD;
&#xD;
          5. Have an evidence of physical examination, vital sign, laboratory examination or&#xD;
             electrocardiographic examination that investigator think can affect this trial;&#xD;
&#xD;
          6. Have an individual or a family history of thyroid C-cell tumors/ carcinoma or with a&#xD;
             history of thyroid dysfunction, thyroid hormone abnormalities or thyroid-related&#xD;
             hormones exceeded the normal range;&#xD;
&#xD;
          7. Have a history of significant illness or medical disorders, including acute or chronic&#xD;
             pancreatitis, cardiovascular disease, renal disorder, hematological disease，hepatic or&#xD;
             gastrointestinal disease, neurological or psychiatric disease, metabolic disorder, or&#xD;
             other diseases that may affect the absorption, distribution, metabolism or excretion&#xD;
             of drugs, such as active gastrointestinal ulcers or bleeding, gastrointestinal&#xD;
             surgery(except appendectomy).&#xD;
&#xD;
          8. Have a history of major surgery within 4 weeks or major minor surgery during the whole&#xD;
             study period;&#xD;
&#xD;
          9. Have a history of smoking or the use of nicotine products or electronic cigarettes,&#xD;
             abusing alcohol or abusing drug within 3 months;&#xD;
&#xD;
         10. Have a presence of prescription or non-prescription drugs, including Chinese&#xD;
             Traditional and Herbal Drugs within 2 weeks; Previous use of glucagon-like peptide-1&#xD;
             analogue or another intestinal insulin, or any unknown cause of infections.&#xD;
&#xD;
         11. Have a presence of any food or drink containing caffeine or xanthine within 48 hours&#xD;
             before administration.&#xD;
&#xD;
         12. Have a history of a New Chemical Entity clinical study within the previous 3 months.&#xD;
&#xD;
         13. Have a presence of pregnancy or lactation.&#xD;
&#xD;
         14. Have a presence of positive hepatitis B surface antigen (HBsAg) or hepatitis C&#xD;
             antibody (anti-HCV), or human immunodeficiency virus (HIV) antibody, or treponema&#xD;
             pallidum antibody.&#xD;
&#xD;
         15. Have a history of blood donation or loss more than 400 ml (including in the frame of a&#xD;
             clinical study) within 3 months before administration;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 16, 2018</study_first_submitted>
  <study_first_submitted_qc>November 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

